P-002 Ide-Cel Real-World (RW) and Clinical Trial Long-Term Safety Experience: A Special Focus on Movement and Neurocognitive Treatment Adverse Events (MNT AEs) and Second Primary Malignancies (SPMs)
Rafat Abonour, Amani Kitali, Adrianna Gipson, Andrew Trovato, Marianne Shanker, Marissa Chiang, Arpitha Gunda, Soyun Park, Anna Truppel-Hartmann, Petra Schuberth, Paula Rodriguez-Otero
{"title":"P-002 Ide-Cel Real-World (RW) and Clinical Trial Long-Term Safety Experience: A Special Focus on Movement and Neurocognitive Treatment Adverse Events (MNT AEs) and Second Primary Malignancies (SPMs)","authors":"Rafat Abonour, Amani Kitali, Adrianna Gipson, Andrew Trovato, Marianne Shanker, Marissa Chiang, Arpitha Gunda, Soyun Park, Anna Truppel-Hartmann, Petra Schuberth, Paula Rodriguez-Otero","doi":"10.1016/S2152-2650(24)01905-0","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"24 ","pages":"Pages S40-S41"},"PeriodicalIF":2.7000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma, Myeloma & Leukemia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2152265024019050","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
期刊介绍:
Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.